很少有可靠的生物标志物可用于远处转移性结直肠癌(CRC)患者。已报道CDH3在晚期CRC患者中异常高表达,但CDH3作为远处转移性CRC患者诊断和预后的生物标志物的价值仍有待评估.在这项研究中,我们探讨了不同阶段CRC患者的CDH3血清水平,并试图确定血清CDH3是否可作为远处转移性CRC患者的独立生物标志物.我们通过ELISA分析了一组CRC(n=96)和正常对照(n=28)的血清CDH3水平。我们比较了正常对照和不同阶段CRCs之间的血清CDH3水平。作为远处转移性CRC的潜在诊断标志物,评估血清CDH3的特异性和敏感性。还进行了多因素分析以确定血清CDH3是否是独立的危险因素。此外,监测并分析姑息性化疗前后血清CDH3水平的变化。在远处转移性CRC中,CDH3,CA24-2,CA19-9,CA72-4和CEA的血清水平显着升高。CA24-2(r=0.24,P=0.01),CA19-9(r=0.20,P=0.03),CA72-4(r=0.64,P<0.0001),CEA(r=0.31,P=0.0012)与CDH3有一定的相关性。经过三个周期的姑息化疗,部分反应CRC的CDH3,CA24-2,CA19-9,CA72-4和CEA水平降低至38.8%(95%置信区间[CI]:30.95%-53.77%),57.73%(95%CI:2.085%-73.83%),50.33%(95%CI:9.935%-79.42%),74.74%(95%CI:25.21%-88.00%),基线的59.16%(95%CI:12.65%-83.56%),分别。CDH3,CA24-2,CA19-9,CA72-4和CEA随化疗反应的受试者工作特征曲线下面积分别为0.900,0.597,0.635,0.608和0.507。血清CDH3是诊断远处转移性CRC和监测远处转移性CRC对姑息性化疗的反应的有效血清生物标志物。
Few robust biomarkers are available for distant metastatic colorectal cancer (CRC) patients. Aberrant high expression of
CDH3 has been reported in advanced CRC patients, but the value of
CDH3 as a biomarker for the diagnosis and prognosis of distant metastatic CRC patients remains to be evaluated. In this study, we explored the serum levels of
CDH3 in different stages of CRC patients and sought to determine whether serum
CDH3 serves as an independent biomarker for distant metastatic CRC patients. We analyzed the serum
CDH3 levels by ELISA in a cohort of CRCs (n=96) and normal controls (n=28). We compared the serum
CDH3 levels between normal controls and different stages of CRCs. As a potential diagnostic marker of distant metastatic CRC, the specificity and sensitivity of serum CDH3 were evaluated. Multivariate analysis was also performed to determine whether serum CDH3 was an independent risk factor. Moreover, the changes of serum CDH3 levels were monitored and analyzed before and after palliative chemotherapy. Serum levels of CDH3, CA24-2, CA19-9, CA72-4, and CEA were significantly elevated in distant metastatic CRCs. CA24-2 (r=0.24, P=0.01), CA19-9 (r=0.20, P=0.03), CA72-4 (r=0.64, P<0.0001), and CEA (r=0.31, P=0.0012) all had a certain correlation with CDH3. After three cycles of palliative chemotherapy, levels of CDH3, CA24-2, CA19-9, CA72-4, and CEA of partial response CRCs were reduced to 38.8% (95% confidence interval [CI]: 30.95%-53.77%), 57.73% (95% CI: 2.085%-73.83%), 50.33% (95% CI: 9.935%-79.42%), 74.74% (95% CI: 25.21%-88.00%), and 59.16% (95% CI: 12.65%-83.56%) of baseline, respectively. The areas under the receiver operating characteristic curves of CDH3, CA24-2, CA19-9, CA72-4, and CEA with chemotherapy response were 0.900, 0.597, 0.635, 0.608, and 0.507, respectively. Serum CDH3 is an effective serum biomarker for the diagnosis of distant metastatic CRCs and monitoring response to palliative chemotherapy in distant metastatic CRCs.